The decrease in cytoplasmic HuR protein levels reduced the therapeutic resistance of ovarian cancer cells [21], and breast cancer cells [22]; a reduction in HuR expression resulted in chemo‐sensitized colorectal cancer cells [20], reduced tumor size [17, 18], and delayed tumor initiation in vivo [17]. This evidence concerns the gene ELAVL1 and breast carcinoma.